Deepak Sarwal, MD
Endocrinology, Diabetes & Metabolism · Dayton, OHNPI 1235159559
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 635 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,111, 2.1 times the $1,962 reported in 2019.
Across 635 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$2K
- Medtronic$1K
- Bayer$1K
- Lilly USA, LLC$963
- Xeris Pharmaceuticals, Inc.$718
- plus $6K from 32 others
Across 8 payments — averaging $7411.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$47K
- GSK$12K
What the payments were for
- Travel & lodging$4383%
- Food & beverage$12,77496%
- Education$1231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 123 | $2,222 |
| Novo Nordisk | 84 | $1,526 |
| Medtronic(2 entities) | 30 | $1,208 |
| Bayer | 55 | $1,162 |
| Lilly USA, LLC | 51 | $963 |
| Xeris Pharmaceuticals, Inc. | 34 | $718 |
| Boehringer Ingelheim | 21 | $632 |
| Johnson & Johnson | 19 | $449 |
| Dexcom, Inc. | 13 | $403 |
| Otsuka America Pharmaceutical, Inc. | 10 | $361 |
| Pfizer | 30 | $360 |
| Insulet Corporation | 20 | $346 |
| Corcept Therapeutics | 24 | $313 |
| Tandem Diabetes Care, Inc. | 9 | $277 |
| BETA Bionics, Inc. | 10 | $277 |
| Abbott | 9 | $268 |
| Astellas Pharma US Inc | 11 | $255 |
| AstraZeneca | 14 | $218 |
| Cequr Corporation | 3 | $213 |
| Evoke Pharma, Inc. | 5 | $163 |
| Amarin Pharma, Inc. | 20 | $153 |
| Sanofi-aventis U.S. LLC | 5 | $142 |
| Merck | 7 | $118 |
| Amphastar Pharmaceuticals, Inc. | 5 | $84 |
| Madrigal Pharmaceuticals | 3 | $75 |
| Novartis | 3 | $61 |
| Biohaven Pharmaceuticals, Inc. | 1 | $47 |
| Mannkind Corporation | 1 | $45 |
| Sequel Med Tech, LLC | 2 | $43 |
| Exact Sciences | 2 | $37 |
| Renalytix AI, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Zealand Pharma US, Inc. | 1 | $31 |
| Lundbeck LLC | 2 | $28 |
| Eisai Inc. | 1 | $27 |
| Bigfoot Biomedical Inc | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$574
- Kerendia$371
- JARDIANCE$369
- iLet Bionic Pancreas$333
- UBRELVY$244
- REXULTI$243
- CeQur Simplicity$184
- t:slim X2 Insulin Pump with Control-IQ$129
- RECORLEV$126
- GIMOTI$125
- GVOKE HYPOPEN$122
- Veozah$122
- XARELTO$122
- VRAYLAR$122
- QULIPTA$120
- RYBELSUS$118
- FreeStyle Libre$114
- MOUNJARO$104
- MINIMED 770G$104
- Wegovy$100
How this compares
$13,335 in reported general payments places this provider in the 80th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 54 | $58,101 |
| OzempicSemaglutide | 37 | $50,826 |
| JardianceEmpagliflozin | 52 | $49,504 |
| EliquisApixaban | 38 | $29,032 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $19,979 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $15,034 |
| LinzessLinaclotide | 21 | $14,526 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,904 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $4,649 |
| Rivastigmine | 13 | $4,412 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 16 | $2,678 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 11 | $2,567 |
| Entacapone | 12 | $2,243 |
| LantusInsulin Glargine,hum.Rec.Anlog | 22 | $2,186 |
| Insulin Lispro | 20 | $1,833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Insulin Lispro | $963 | $59,93474 claims |
| Novo NordiskOzempic | $1,526 | $50,82637 claims |
| Boehringer IngelheimJardiance | $632 | $49,50452 claims |
| PfizerEliquis | $360 | $29,03238 claims |
| AbbVieLinzess, Synthroid | $2,222 | $15,58944 claims |
| Sanofi-aventis U.S. LLCLantus | $142 | $2,18622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Dayton
- Trisha ZeidanDayton$124K
- Elena ChristofidesColumbus$2.3M
- Kevin PantaloneCleveland$1.2M
- John PaesWesterville$671K
- Samuel AndersonColumbus$556K
- Bhaskar GundaboluToledo$471K
- Nelson WattsCincinnati$346K
- Baker MachhadiehHamilton$304K
- Brian BurtchMentor$264K
- Allan KennedyCleveland$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.